Baylor College of Medicine

NEPTUNUS (H-52378)

Description

Content

A randomized, double-blind, placebo-controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren’s syndrome (NEPTUNUS-1).
 

IRB: H-52378

Status:

Active

Created:

Back to topback-to-top